Cancer Network speaks with Dr. Pavel Sumazin about his ongoing efforts to further understand how lncRNA influence genes with known function in cancers.
A study shows sequential monitoring of the WT1 mRNA is of value for the early detection of hematologic relapse in patients with AML in remission.
Azacitidine may delay or prevent relapse among patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome.
Professor Lana E. Kandalaft, PharmD, PhD spoke with Cancer Network about the next generation of cancer immunotherapy.
Guy Ben-Betzalel, MD spoke with Cancer Network about the emerging role of targeted BRAF+MEK inhibition in antitumor immunity.
Professor Han Liang speaks with Cancer Network about the ubiquitin pathway and its role in cancer research.
Guang Peng, MD, PhD spoke to Cancer Network about the recent discovery that mTORC1 can help determine cell fate after DNA damage.
The FDA authorized the first next-generation sequencing test to detect minimal residual disease in blood cancers.
A study shows gene variants of uncertain significance are frequently reclassified, necessitating amended test result reports.
A study shows TRK gene fusions in hematologic cancers may respond to larotrectinib.